A Phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer

Trial Profile

A Phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Tisotumab-vedotin (Primary)
  • Indications Cervical cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 11 Oct 2017 New trial record
    • 10 Oct 2017 According to a company media release, Genmab and Seattle Genetics plan to start enrolling patients by the first half of 2018. This trial could provide the basis for a regulatory application for approval.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top